Press Releases

Today BlueSphere Bio announces the appointment of Jonathan Peacock as Chairman of the Board of Directors in its pursuit to build an industry leading Board and executive team to develop their groundbreaking immune oncology T cell receptor (TCR) T-cell discovery platform and clinical programs. Mr. Peacock brings a wealth of experience from the biotech and […]

Immuno-oncology startup BlueSphere Bio, a company developing its novel T cell receptor search and capture platform, TCXpress, to create rapid personalized T cell therapies for cancer and blood and marrow transplantation, has named immunotherapy pioneer Alan Korman, Ph.D., to its board of directors. Korman brings more than three decades of immunotherapy and biotechnology experience to

BlueSphere Bio, which was established by UPMC Enterprises, uses its novel TCXpress platform to obtain and characterize T cell receptors, the key component for any T cell immunotherapy. This technology, developed at the University of Pittsburgh, is an efficient, cost-effective alternative to conventional methods of using a person’s own T cells to create individualized treatments.

BlueSphere Bio, an immunotherapy startup focused on creating personalized T cell therapies for cancer, today announced the members of its newly formed scientific advisory board. Composed of internationally renowned scientists with deep expertise that spans basic T cell immunology to cutting edge adoptive T cell immunotherapies, the board will provide vital guidance for BlueSphere Bio

BlueSphere Bio, an immunotherapy startup formed by UPMC Enterprises and focused on creating personalized therapies for cancer, announced today that David Apelian, M.D., Ph.D., M.B.A., has been named chief executive officer of the company. He joins top clinical immunology experts and company co-founders Mark Shlomchik, M.D., Ph.D., and Warren Shlomchik, M.D., of the University of